Canine Arthritis Treatment Market Growth Opportunities, 2034

Canine Arthritis Treatment Market Outlook from 2024 to 2034

The global canine arthritis treatment market stands at a valuation of US$ 2.50 billion in 2024. Global demand for canine arthritis treatment medications is predicted to rise at a CAGR of 4.20% and attain a market valuation of US$ 3.77 billion by 2034.

Attributes	Key Statistics
Expected Base Year Value (2024)	US$ 2.50 billion
Anticipated Forecast Value (2034)	US$ 3.77 billion
Estimated Growth (2024 to 2034)	4.20% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Market Drivers

The canine arthritis treatment industry generated a valuation of US$ 1.97 billion in 2018. The market grew at a rate of 5.0% CAGR over five years, generating an additional US$ 550 million in valuation by 2023.

This growth can be attributed to various factors:

Increased awareness among pet owners about the importance of arthritis management for their canine companions, leading to earlier diagnosis and treatment initiation
Advancements in veterinary pharmaceuticals, such as new pain management medications and joint supplements, provide more effective options for arthritis relief
Expansion of veterinary services offering specialized treatments like acupuncture, hydrotherapy, and physical therapy, improving access to comprehensive arthritis care for dogs
Growing demand for minimally invasive surgical procedures for arthritis treatment due to pet owners' desire for less invasive yet effective solutions
Rise in pet insurance coverage, allowing more pet owners to afford arthritis treatments for their dogs, driving increased utilization of veterinary services
Adoption of preventive healthcare measures to address arthritis risk factors early on, highlighting the importance of proactive management in maintaining canine joint health
Development of innovative technologies like regenerative medicine for arthritis treatment, promising novel approaches to alleviate joint pain and improve mobility in dogs
The aging pet population leading to a higher prevalence of arthritis cases, underscoring the need for ongoing advancements in arthritis management strategies
Increasing disposable income among pet owners, facilitating greater investment in advanced arthritis treatments, and enhancing the overall quality of care for arthritic dogs
Strong emphasis on improving the quality of life and mobility for arthritic dogs, driving demand for effective treatment options due to the evolving attitudes towards pets as valued family members.

Consumption Analysis of the Canine Arthritis Treatment Market

Sales of canine arthritis treatments are growing among veterinary professionals, veterinary technicians, and other staff members, who diagnose, prescribe, and administer arthritis treatments to dogs
Canine arthritis treatments are also experiencing increasing demand from pet owners who own dogs affected by arthritis and seek out treatments to improve their pets' comfort and quality of life
The growing adoption of canine arthritis treatments is also observed among et insurance companies that provide coverage for veterinary expenses and help pet owners afford necessary care for their arthritic dogs
Pet product retailers are also some of the largest consumer groups in this market. These entities seek arthritis treatments for their canine companions, providing access to medications, supplements, and other supportive products
Veterinary clinics and pet care facilities generate great demand for canine arthritis treatments. These entities utilize canine arthritis treatments to address joint pain and mobility issues in dogs under their care.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Hesitation Among Pet Owners to Slow Down the Market Growth for Canine Arthritis Treatments

The canine arthritis treatment market is anticipated to grow at a modest CAGR of 4.20% till 2034. This is attributed to several reasons:

Canine arthritis treatments, in most cases, are hindered due to limited access to affordable veterinary care in certain regions, especially the underdeveloped and developing parts of the world.
Some pet owners are hesitant to try new medications or therapies due to concerns regarding the safety and efficacy of certain arthritis treatments. This leads to potential gaps in treatment, slowing down the market.
Traditional pharmaceutical treatments for canine arthritis also face competition from alternative treatments such as physical therapy, acupuncture, and chiropractic care. This is significantly diverting the consumer base.
Limited awareness and education among pet owners about early intervention and long-term management of arthritis in dogs is resulting in delayed diagnosis. This is detrimental to the health of the pet, which has to undergo a lot of pain.

Comparative View of Adjacent Industries

Future Market Insights has comprehensively analyzed the global healthcare sector and has studied two markets alongside the canine arthritis treatment market--the veterinary vaccines market and the animal healthcare market. The growth rates and the current market valuation have been mentioned in the table below. The growth factors and critical challenges in the respective markets have also been discussed below.

Canine Arthritis Treatment Market:

Attributes	Canine Arthritis Treatment Market
CAGR (2024 to 2034)	4.20%
Market Value (2024)	US$ 2.50 billion
Growth Factor	Increased awareness among pet owners about the importance of arthritis management for their canine companions
Challenges	Hesitancy among pet owners to try new medications or therapies due to concerns regarding the safety and efficacy

Animal Healthcare Market:

Attributes	Animal Healthcare Market
CAGR (2023 to 2033)	4.30%
Market Value (2023)	US$ 40.9 billion
Growth Factor	Growing awareness about maintaining the proper health of animals, and surging demand for animal pharmaceuticals for enhancing the immunity system of animals.
Challenges	Increasing restrictions imposed by regulatory authorities in some countries on the usage of antibiotics

Veterinary Vaccines Market:

Attributes	Veterinary Vaccines Market
CAGR (2023 to 2033)	6.20%
Market Value (2022)	US$ 11.3 billion
Growth Factor	The rising prevalence of zoonotic diseases, increasing demand for animal products, and growing trend of pet adoption across the world
Challenges	The lack of awareness and accessibility for smaller farmers, low healthcare awareness in some regions, and the possibility of harmful outcomes of animal vaccinations

Category-wise Insights

Pet Owners are Increasingly Preferring NSAIDs for Canine Arthritis Treatments

The NSAIDs category is projected to hold the largest share of the canine arthritis treatment market in the year 2024. This segment holds the dominant market share, accounting for 72% of the global canine arthritis treatment market.

The demand for NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) has skyrocketed in the last few decades as they are considered highly effective in relieving pain and inflammation associated with canine arthritis.
Veterinary professionals are also prescribing NSAIDs due to their proven effectiveness and safety profile in managing arthritis symptoms in dogs. This has made NSAIDs the most sought-after treatment option for pet owners.

Attributes	Details
Drug Class	NSAIDs
Market Share	72.00%

Veterinary Professionals are Prescribing Oral Treatments for Canine Arthritis

The canine arthritis treatment market is also categorized by route of administration into oral and injectable canine arthritis treatment. The oral segment dominates the market with a share of 70% in 2024.

Pet owners, as well as veterinary professionals, are increasingly choosing oral treatments as they offer a convenient administration route for them. This allows for easy integration into a dog's daily routine.
The demand for oral routes in canine arthritis treatments is also surging as they provide flexibility in dosing and administration schedules. This minimizes the risk of complications associated with injectable therapies, such as injection site reactions.

Attributes	Details
Route of Administration	Oral
Market Share	70.00%

Country-wise Insights

The section provides an analysis of the canine arthritis treatment market by country, including India, Spain, Italy, Australia, and France. The table presents the CAGR for each country, indicating the expected growth of the market in that country through 2034.

Countries	CAGR
Spain	5.50%
India	5.30%
Italy	4.90%
Australia	4.70%
France	4.60%

Growing Awareness about Arthritis in Dogs is pushing the Demand for Treatments in India

India is expected to exhibit significant market growth over the forecast period. The Indian market for canine arthritis treatments is anticipated to grow at a CAGR of 5.30% through 2034.

The growing awareness among Indian pet owners about the significance of veterinary care, including arthritis management, is driving the demand for treatment options.
The emerging middle class in India with more disposable income to spend on pet healthcare, including arthritis treatments. This is significantly fuelling market growth in the country.

Pet Humanization Trend to Boost Market Growth in Spain

Spain is also one of the lucrative markets in the canine arthritis treatment industry. The Spanish market for canine arthritis treatments is anticipated to grow at a CAGR of 5.50% through 2034.

Spain is witnessing a trend of pet humanization, where dogs are considered valued family members. This has resulted in an increased investment in their healthcare, including arthritis treatment.
The pet insurance market in Spain is also experiencing a significant surge in the recent past. This has helped pet owners afford expensive treatments, like arthritis subsequently contributing to the growth of this market.

Significant Population of Aging Dogs in Italy to Augment Market Growth

Italy also is a promising market in the global canine arthritis treatment industry. Over the next ten years, the Italian demand for canine arthritis treatments is projected to rise at a 4.90% CAGR.

The changing lifestyles in Italy, with more people living in urban areas and smaller homes, have led to an increased focus on pet health. This is also one of the main drivers for the exponential growth of this market in the country.
Italy has a significant population of aging dogs. This has led to a higher prevalence of arthritis and, thus, an increased demand for canine treatments in the country.

Pet-friendly Policies to Shape the Future of Canine Arthritis Market in Australia

Australia is also one of the countries that is filled with potential in this market. The Australian canine arthritis treatment market is anticipated to retain its dominance by progressing at a growth rate of 4.70% till 2034.

Australia's outdoor lifestyle contributes to a high level of physical activity for dogs. This has increased the risk of arthritis and, thus, driving demand for canine arthritis treatment options in the country.
Australia also has considerable pet-friendly policies and regulations. This encourages a supportive environment for pet healthcare, including arthritis treatment.

High-standard Veterinary Care to Boost the Market Growth in France

France also exhibits a promising future in the global canine arthritis treatment market. The canine arthritis treatment market in France is anticipated to retain its dominance by progressing at a growth rate of 4.60% till 2034.

France is known for its high standard of veterinary care, with skilled professionals offering advanced arthritis treatment solutions for dogs. This is one of the main reasons for the country’s position in the global market.
France's pet-friendly culture, with dogs being considered integral members of many households, also drives demand for arthritis treatment options.

Competitive Landscape

Major companies and manufacturers in the canine arthritis treatment market, such as Boehringer Ingelheim International GmbH., DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., DSM, etc., investing heavily in research and development to innovate new medications, supplements, and therapeutic approaches.

These companies are also expanding their distribution networks and partnerships with veterinary clinics, pet retailers, and online platforms to enhance the market reach and accessibility of their products to pet owners.

Recent Developments:

In January 2023, TVM introduced DogStem, Europe's inaugural licensed stem cell therapy for canine osteoarthritis. Clinical trials demonstrated its efficacy, with improvements in gait and orthopedic examination, and owners reported enhanced mobility and quality of life for their pets, lasting up to eighteen months.
In May 2019, Elanco launched Galliprant, a new treatment for canine osteoarthritis pain, in the UK. Galliprant, a piprant, targets the EP4 receptor, reducing pain and inflammation without affecting gastrointestinal and kidney functions, offering a promising solution for managing OA discomfort in dogs.
In February 2024, Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis, aiming to address the condition's widespread prevalence and devastating consequences, potentially revolutionizing dog health.

Key Companies in the Market

Boehringer Ingelheim International GmbH
DAIICHI SANKYO COMPANY, LIMITED
Thorne
NUTRI-VET
American Regent, Inc.
DSM
Zoetis
National hog farmer
Novasep
Bayer AG
Matsun Nutrition

Key Coverage in the Canine arthritis treatment Industry Report

Demand Analysis for Canine Arthritis Management Injection
Key Mergers and Acquisitions in the Canine Arthritis Treatment Market
Best Canine Osteoarthritis Treatment in India
Demand Analysis for Canine Osteoarthritis Therapy
General Overview of Dog Arthritis Medication Side Effects

Canine arthritis treatment Market by Segmentation

By Treatment:

Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Opioids
Stem Cell Therapy
Allogeneic Stem Cells
Autologous Stem Cells

By Route of Administration:

Oral Canine Arthritis Treatment
Injectable Canine Arthritis Treatment

By Distribution Channel:

Veterinary Hospitals & Clinics
Retail Pharmacies
Drug Stores
e-Commerce

By Region:

North America
Latin America
Asia Pacific
Middle East and Africa (MEA)
Europe

Frequently Asked Questions

How much is the Canine Arthritis Treatment Market Currently Worth?

The global canine arthritis treatment market is expected to be worth US$ 2.50 billion by 2024.

What is the Sales Forecast for Canine Arthritis Treatments through 2034?

The market for canine arthritis treatments is expected to reach US$ 3.77 billion by 2034.

At what rate is the Canine Arthritis Treatment Market growing across the world?

The canine arthritis treatment market is growing at a CAGR of 4.20% from 2024 to 2034.

Who are the key Companies in the Canine Arthritis Treatment Market?

Boehringer Ingelheim International GmbH., DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., DSM, etc. are some of the major players in the market for canine arthritis treatment.

What was the overall Global Value of the Canine Arthritis Treatment Market in 2023?

The global valuation for the canine arthritis treatment market in 2023 was US$ 2.52 billion.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2024 to 2034

        5.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

        5.3.2. Opioids

        5.3.3. Stem Cell Therapy

        5.3.4. Allogeneic Stem Cells

        5.3.5. Autologous Stem Cells

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Treatment, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024 to 2034

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034

        7.3.1. Veterinary Hospitals & Clinics

        7.3.2. Retail Pharmacies

        7.3.3. Drug Stores

        7.3.4. E-Commerce

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Treatment

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Treatment

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Treatment

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Treatment

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Treatment

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Treatment

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Market Share Analysis, 2023

            16.1.1.1. By Treatment

            16.1.1.2. By Route of Administration

            16.1.1.3. By Distribution Channel

    16.2. Canada

        16.2.1. Market Share Analysis, 2023

            16.2.1.1. By Treatment

            16.2.1.2. By Route of Administration

            16.2.1.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Market Share Analysis, 2023

            16.3.1.1. By Treatment

            16.3.1.2. By Route of Administration

            16.3.1.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Market Share Analysis, 2023

            16.4.1.1. By Treatment

            16.4.1.2. By Route of Administration

            16.4.1.3. By Distribution Channel

    16.5. Germany

        16.5.1. Market Share Analysis, 2023

            16.5.1.1. By Treatment

            16.5.1.2. By Route of Administration

            16.5.1.3. By Distribution Channel

    16.6. UK

        16.6.1. Market Share Analysis, 2023

            16.6.1.1. By Treatment

            16.6.1.2. By Route of Administration

            16.6.1.3. By Distribution Channel

    16.7. France

        16.7.1. Market Share Analysis, 2023

            16.7.1.1. By Treatment

            16.7.1.2. By Route of Administration

            16.7.1.3. By Distribution Channel

    16.8. Spain

        16.8.1. Market Share Analysis, 2023

            16.8.1.1. By Treatment

            16.8.1.2. By Route of Administration

            16.8.1.3. By Distribution Channel

    16.9. Italy

        16.9.1. Market Share Analysis, 2023

            16.9.1.1. By Treatment

            16.9.1.2. By Route of Administration

            16.9.1.3. By Distribution Channel

    16.10. Poland

        16.10.1. Market Share Analysis, 2023

            16.10.1.1. By Treatment

            16.10.1.2. By Route of Administration

            16.10.1.3. By Distribution Channel

    16.11. Russia

        16.11.1. Market Share Analysis, 2023

            16.11.1.1. By Treatment

            16.11.1.2. By Route of Administration

            16.11.1.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Market Share Analysis, 2023

            16.12.1.1. By Treatment

            16.12.1.2. By Route of Administration

            16.12.1.3. By Distribution Channel

    16.13. Romania

        16.13.1. Market Share Analysis, 2023

            16.13.1.1. By Treatment

            16.13.1.2. By Route of Administration

            16.13.1.3. By Distribution Channel

    16.14. India

        16.14.1. Market Share Analysis, 2023

            16.14.1.1. By Treatment

            16.14.1.2. By Route of Administration

            16.14.1.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Market Share Analysis, 2023

            16.15.1.1. By Treatment

            16.15.1.2. By Route of Administration

            16.15.1.3. By Distribution Channel

    16.16. Australia

        16.16.1. Market Share Analysis, 2023

            16.16.1.1. By Treatment

            16.16.1.2. By Route of Administration

            16.16.1.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Market Share Analysis, 2023

            16.17.1.1. By Treatment

            16.17.1.2. By Route of Administration

            16.17.1.3. By Distribution Channel

    16.18. China

        16.18.1. Market Share Analysis, 2023

            16.18.1.1. By Treatment

            16.18.1.2. By Route of Administration

            16.18.1.3. By Distribution Channel

    16.19. Japan

        16.19.1. Market Share Analysis, 2023

            16.19.1.1. By Treatment

            16.19.1.2. By Route of Administration

            16.19.1.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Market Share Analysis, 2023

            16.20.1.1. By Treatment

            16.20.1.2. By Route of Administration

            16.20.1.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Market Share Analysis, 2023

            16.21.1.1. By Treatment

            16.21.1.2. By Route of Administration

            16.21.1.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Market Share Analysis, 2023

            16.22.1.1. By Treatment

            16.22.1.2. By Route of Administration

            16.22.1.3. By Distribution Channel

    16.23. Israel

        16.23.1. Market Share Analysis, 2023

            16.23.1.1. By Treatment

            16.23.1.2. By Route of Administration

            16.23.1.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Treatment

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Boehringer Ingelheim International GmbH.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. DAIICHI SANKYO COMPANY, LIMITED

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Thorne

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Nutri-Vet

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. American Regent, Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. DSM

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Zoetis

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. National Hog Farmer

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Novasep

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Bayer AG

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Matsun Nutrition

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Canine Arthritis Treatment Market

Canine Arthritis Treatment Market Forecast by Opioids and Stem Cell Therapy for 2024 to 2034